$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

$jazz Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000123252416000271 Filed on May 10, 2016

Income Statement

Concept	2016 Q1	2015 Q1
Revenue	$336.0M	$309.3M
YoY Change	8.63%	25.26%
Cost Of Revenue	$23.40M	$28.30M
YoY Change	-17.31%	-8.41%
Gross Profit	$310.5M	$278.7M
YoY Change	11.39%	30.21%
Gross Profit Margin	92.4%	90.12%
Selling, General & Admin	$128.8M	$112.4M
YoY Change	14.57%	5.66%
% of Gross Profit	41.47%	40.32%
Research & Development	$31.25M	$27.18M
YoY Change	14.98%	50.1%
% of Gross Profit	10.07%	9.75%
Depreciation & Amortization	$2.527M	$2.232M
YoY Change	13.22%	70.51%
% of Gross Profit	0.81%	0.8%
Operating Expenses	$214.8M	$192.5M
YoY Change	11.58%	-38.6%
Operating Profit	$121.2M	$116.8M
YoY Change	3.77%	-275.16%
Interest Expense	-$12.19M	-$16.25M
YoY Change	-24.95%	61.22%
% of Operating Profit	-10.06%	-13.91%
Other Income/Expense, Net	-$819.0K	$2.245M
YoY Change	-136.48%
Pretax Income	$108.2M	$102.8M
YoY Change	5.25%	-234.13%
Income Tax	$32.34M	$32.06M
% Of Pretax Income	29.9%	31.2%
Net Earnings	$75.81M	$70.70M
YoY Change	7.23%	-176.31%
Net Earnings / Revenue	22.56%	22.86%
Basic Earnings Per Share	$1.24	$1.16
Diluted Earnings Per Share	$1.21	$1.12
COMMON SHARES
Basic Shares Outstanding	61.14M shares	60.80M shares
Diluted Shares Outstanding	62.62M shares	62.96M shares

Balance Sheet

Concept	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$980.5M	$782.6M
YoY Change	25.29%	211.3%
Cash & Equivalents	$979.8M	$782.6M
Short-Term Investments	$800.0K	$783.0M
Other Short-Term Assets	$22.43M	$21.52M
YoY Change	4.22%	-9.37%
Inventory	$25.37M	$30.69M
Prepaid Expenses	$18.47M	$27.61M
Receivables	$223.8M	$189.7M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.271B	$1.103B
YoY Change	15.2%	113.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$86.79M	$71.28M
YoY Change	21.75%	137.23%
Goodwill	$671.0M	$654.5M
YoY Change	2.52%	-14.31%
Intangibles	$1.348B	$1.284B
YoY Change	4.97%	-26.86%
Long-Term Investments
YoY Change
Other Assets	$29.54M	$19.19M
YoY Change	53.96%	106.42%
Total Long-Term Assets	$2.264B	$2.135B
YoY Change	6.08%	-20.32%
TOTAL ASSETS
Total Short-Term Assets	$1.271B	$1.103B
Total Long-Term Assets	$2.264B	$2.135B
Total Assets	$3.535B	$3.238B
YoY Change	9.19%	1.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$32.62M	$27.32M
YoY Change	19.42%	-62.34%
Accrued Expenses	$307.5M	$147.0M
YoY Change	109.22%	-0.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$37.59M	$9.388M
YoY Change	300.43%	-1.31%
Total Short-Term Liabilities	$398.8M	$220.6M
YoY Change	80.81%	-7.32%
LONG-TERM LIABILITIES
Long-Term Debt	$1.146B	$1.335B
YoY Change	-14.1%	12.24%
Other Long-Term Liabilities	$79.21M	$45.12M
YoY Change	75.54%	77.68%
Total Long-Term Liabilities	$1.226B	$1.380B
YoY Change	-11.17%	13.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$398.8M	$220.6M
Total Long-Term Liabilities	$1.226B	$1.380B
Total Liabilities	$1.624B	$1.600B
YoY Change	1.51%	10.18%
SHAREHOLDERS EQUITY
Retained Earnings	$242.4M	$95.07M
YoY Change	155.02%	-228.26%
Common Stock	$1.587B	$1.488B
YoY Change	6.62%	18.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.709B	$1.305B
YoY Change
Total Liabilities & Shareholders Equity	$3.535B	$3.238B
YoY Change	9.19%	1.29%

Cashflow Statement

Concept	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	$75.81M	$70.70M
YoY Change	7.23%	-176.31%
Depreciation, Depletion And Amortization	$2.527M	$2.232M
YoY Change	13.22%	70.51%
Cash From Operating Activities	$151.7M	$96.56M
YoY Change	57.06%	40.5%
INVESTING ACTIVITIES
Capital Expenditures	-$11.20M	-$14.40M
YoY Change	-22.22%	-88.79%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	-$800.0K	$32.70M
YoY Change	-102.45%	-103.95%
Cash From Investing Activities	-$12.00M	$18.29M
YoY Change	-165.57%	-101.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$134.4M	$10.34M
YoY Change	1199.72%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$152.5M	-$3.261M
YoY Change	4575.19%	-100.66%
NET CHANGE
Cash From Operating Activities	$151.7M	$96.56M
Cash From Investing Activities	-$12.00M	$18.29M
Cash From Financing Activities	-$152.5M	-$3.261M
Net Change In Cash	-$12.80M	$111.6M
YoY Change	-111.47%	-128.55%
FREE CASH FLOW
Cash From Operating Activities	$151.7M	$96.56M
Capital Expenditures	-$11.20M	-$14.40M
Free Cash Flow	$162.9M	$111.0M
YoY Change	46.77%	-43.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001232524
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60421794	shares
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	Jazz Pharmaceuticals plc
CY2016Q1	dei	Trading Symbol TradingSymbol	JAZZ
CY2015Q4	jazz	Accrued Construction In Progress AccruedConstructionInProgress	1637000	USD
CY2016Q1	jazz	Accrued Construction In Progress AccruedConstructionInProgress	1157000	USD
CY2015Q4	jazz	Accrued Interest AccruedInterest	4043000	USD
CY2016Q1	jazz	Accrued Interest AccruedInterest	1348000	USD
CY2015Q4	jazz	Accrued Milestone Payments AccruedMilestonePayments	0	USD
CY2016Q1	jazz	Accrued Milestone Payments AccruedMilestonePayments	150000000	USD
CY2015Q4	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	67454000	USD
CY2016Q1	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	71153000	USD
CY2015Q4	jazz	Capital Redemption Reserve CapitalRedemptionReserve	471000	USD
CY2016Q1	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	USD
CY2015Q4	jazz	Computer Equipment Gross ComputerEquipmentGross	10963000	USD
CY2016Q1	jazz	Computer Equipment Gross ComputerEquipmentGross	10798000	USD
CY2015Q4	jazz	Contract Claim Settlement Liabilities Current ContractClaimSettlementLiabilitiesCurrent	18000000	USD
CY2016Q1	jazz	Contract Claim Settlement Liabilities Current ContractClaimSettlementLiabilitiesCurrent	0	USD
CY2015Q1	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	28298000	USD
CY2016Q1	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	23439000	USD
CY2015Q4	jazz	Entity Wide Accounts Receivable Major Customer Percentage EntityWideAccountsReceivableMajorCustomerPercentage	0.90
CY2016Q1	jazz	Entity Wide Accounts Receivable Major Customer Percentage EntityWideAccountsReceivableMajorCustomerPercentage	0.91
CY2015Q4	jazz	Landand Buildings Gross LandandBuildingsGross	1775000	USD
CY2016Q1	jazz	Landand Buildings Gross LandandBuildingsGross	1838000	USD
CY2015Q4	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2016Q1	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2015Q4	jazz	Number Of Customers With Significant Accounts Receivable Balance NumberOfCustomersWithSignificantAccountsReceivableBalance	5	Customer
CY2016Q1	jazz	Number Of Customers With Significant Accounts Receivable Balance NumberOfCustomersWithSignificantAccountsReceivableBalance	5	Customer
CY2015Q1	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	0	USD
CY2016Q1	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	8750000	USD
CY2015Q1	jazz	Proceeds From Employee Stock Purchases And Exercise Of Stock Options And Warrants ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptionsAndWarrants	13504000	USD
CY2016Q1	jazz	Proceeds From Employee Stock Purchases And Exercise Of Stock Options And Warrants ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptionsAndWarrants	3780000	USD
CY2015Q1	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	426000	USD
CY2016Q1	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	898000	USD
CY2015Q1	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	2268000	USD
CY2016Q1	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	2094000	USD
CY2015Q4	jazz	Sales Return Reserve SalesReturnReserve	6110000	USD
CY2016Q1	jazz	Sales Return Reserve SalesReturnReserve	5736000	USD
CY2015Q1	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	13504000	USD
CY2016Q1	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	3780000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21807000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	32622000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	209685000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	223802000	USD
CY2015Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	35595000	USD
CY2016Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	28634000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	164070000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	307504000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3038000	USD
CY2016Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3446000	USD
CY2015Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4211000	USD
CY2016Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5679000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23680000	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25205000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-267472000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-222284000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1562900000	USD
CY2016Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1586750000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation	14778000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation	12476000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20896000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24608000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	10635000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	7938000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20819000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24183000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	14665000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	17220000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	6016000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5362000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	24677000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22642000	USD
CY2015Q4	us-gaap	Assets Assets	3343604000	USD
CY2016Q1	us-gaap	Assets Assets	3534979000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	1257667000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	1270618000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	988785000	USD
CY2016Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	980544000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	988785000	USD
CY2016Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	980544000	USD
CY2015Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	15797000	USD
CY2016Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	15273000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	684042000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	782603000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	988785000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	979780000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	98561000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9005000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85787000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	119309000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-10000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-85797000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	119309000	USD
CY2015Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	63008000	USD
CY2016Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	66185000	USD
CY2016Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1306759000	USD
CY2015Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	7209000	USD
CY2016Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	6843000	USD
CY2015Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9261000	USD
CY2016Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1962000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1370000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1378000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3721000	USD
CY2016Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3441000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	122863000	USD
CY2016Q1	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	122036000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	294485000	USD
CY2016Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	299627000	USD
CY2015Q1	us-gaap	Depreciation Depreciation	2232000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	2527000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.16
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.21
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.12
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.19
CY2015Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-13026000	USD
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	3794000	USD
CY2015Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.312
CY2016Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.315
CY2015Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	6154000	USD
CY2016Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	6963000	USD
CY2015Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	10635000	USD
CY2016Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	7938000	USD
CY2015Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	10635000	USD
CY2016Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	7938000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	332602000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	359922000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	708139000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	80539000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	103044000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	104255000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	104480000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	107385000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1335903000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1567764000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1003301000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1207842000	USD
CY2015Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2580000	USD
CY2016Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2605000	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-37000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	657139000	USD
CY2016Q1	us-gaap	Goodwill Goodwill	670991000	USD
CY2016Q1	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	13852000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	102759000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	108151000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32059000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34030000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3303000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10664000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4769000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13802000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	30163000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	25758000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-17485000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6706000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-285000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-266000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1842000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6307000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3278000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1985000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	6820000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	7392000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	15670000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1231000	USD
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2161000	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1332000	shares
CY2015Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1518208000	USD
CY2016Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1708082000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1185606000	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1348160000	USD
CY2015Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-16245000	USD
CY2016Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-12192000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5007000	USD
CY2016Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	8349000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	19451000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	25369000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2608000	USD
CY2016Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2145000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11836000	USD
CY2016Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	14875000	USD
CY2015Q4	us-gaap	Investments Investments	0	USD
CY2016Q1	us-gaap	Investments Investments	764000	USD
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	9301000	USD
CY2016Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	9262000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3343604000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3534979000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	226642000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	398831000	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	1188444000	USD
CY2016Q1	us-gaap	Long Term Debt LongTermDebt	1184025000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	37587000	USD
CY2016Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	37592000	USD
CY2016Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	575000000	USD
CY2016Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	520452000	USD
CY2016Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	79793000	USD
CY2016Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	61038000	USD
CY2016Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	42283000	USD
CY2016Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	28193000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1150857000	USD
CY2016Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1146433000	USD
CY2015Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	5828000	USD
CY2016Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	6032000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3261000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-144520000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18293000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11995000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	96555000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	143716000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	70700000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	74121000	USD
CY2016Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	192544000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	214848000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	116759000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	121162000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	111321000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	6715000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	7277000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	8552000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	13014000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	66588000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	9175000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	23982000	USD
CY2016Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	40351000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	19047000	USD
CY2016Q1	us-gaap	Other Assets Current OtherAssetsCurrent	22431000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27548000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29543000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-156497000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	45188000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-156497000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	45188000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-156497000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	45188000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	69253000	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	79207000	USD
CY2015Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5384000	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1579000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2245000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-819000	USD
CY2015Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	0	USD
CY2016Q1	us-gaap	Other Short Term Investments OtherShortTermInvestments	764000	USD
CY2015Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	10338000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	134365000	USD
CY2015Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	14778000	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	12476000	USD
CY2015Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2016Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	773000	USD
CY2015Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	14410000	USD
CY2016Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2472000	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	20699000	USD
CY2016Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18472000	USD
CY2015Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	32703000	USD
CY2016Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2015Q1	us-gaap	Profit Loss ProfitLoss	70700000	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	74121000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	109252000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	111993000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	85572000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	86788000	USD
CY2015Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	2284000	USD
CY2016Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	9397000	USD
CY2015Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
CY2016Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	8750000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27181000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31252000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	302686000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	242441000	USD
CY2015Q1	us-gaap	Revenues Revenues	309303000	USD
CY2016Q1	us-gaap	Revenues Revenues	336010000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	307035000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	333916000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	112388000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	128765000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	20819000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	24183000	USD
CY2015Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	10338000	USD
CY2016Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	134365000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1371208000	USD
CY2015Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1305330000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1598646000	USD
CY2016Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1607440000	USD
CY2015Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	1808000	USD
CY2016Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	19735000	USD
CY2016Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	53400000	USD
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62964000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62474000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60803000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61142000	shares
CY2016Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and marketable securities. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the United States, and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> customers accounted for </font><font style="font-family:inherit;font-size:10pt;">91%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliates, or Express Scripts, which accounted for </font><font style="font-family:inherit;font-size:10pt;">70%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable and McKesson Corporation and its affiliates, or McKesson, which accounted for </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> customers accounted for </font><font style="font-family:inherit;font-size:10pt;">90%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, including Express Scripts, which accounted for </font><font style="font-family:inherit;font-size:10pt;">69%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, and IDIS Limited, or IDIS, which accounted for </font><font style="font-family:inherit;font-size:10pt;">11%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We depend on single source suppliers for each of our products, product candidates and their active pharmaceutical ingredients.</font></div></div>
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001232524-16-000271-index-headers.html	Edgar Link	pending
0001232524-16-000271-index.html	Edgar Link	pending
0001232524-16-000271.txt	Edgar Link	pending
0001232524-16-000271-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
jazz-20160331.xml	Edgar Link	completed
jazz-20160331.xsd	Edgar Link	pending
jazz-20160331_cal.xml	Edgar Link	unprocessable
jazz-20160331_def.xml	Edgar Link	unprocessable
jazz-20160331_lab.xml	Edgar Link	unprocessable
jazz-20160331_pre.xml	Edgar Link	unprocessable
jazz2016q1doc.htm	Edgar Link	pending
jazzq12016ex101.htm	Edgar Link	pending
jazzq12016ex102.htm	Edgar Link	pending
jazzq12016ex311.htm	Edgar Link	pending
jazzq12016ex312.htm	Edgar Link	pending
jazzq12016ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

2016 Q1 Form 10-Q Financial Statement

#000123252416000271 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ Jazz Pharmaceuticals PLC Stock $jazz

2016 Q1 Form 10-Q Financial Statement

#000123252416000271 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz